Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: Saliva as a surrogate of pharmacokinetics in the central compartment

Epilepsia

Volumn 54, Issue 1, 2013, Pages 81-88

  Cawello, Willi ^a   Bökens, Hilmar ^a   Nickel, Brunhild ^a   Andreas, Jens Otto ^a   Halabi, Atef ^b  

^a UCB PHARMA   (Belgium)

^b CRS Clinical Research Services Kiel GmbH   (Germany)

Author keywords

Bioequivalence; Lacosamide; Pharmacokinetics; Saliva; Syrup

Indexed keywords

2 DESMETHYL HARKOSERIDE; DRUG METABOLITE; HARKOSERIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG SALIVA LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SINGLE DRUG DOSE; SYRUP; TABLET FORMULATION;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; MALE; SALIVA; TABLETS; YOUNG ADULT;

EID: 84872086635     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03725.x     Document Type: Article

References (25)

1. Boucaud M, Pinguet F, Culine S, Poujol S, Astre C, Gomeni R, Bressolle F,. (2003) Modeling plasma and saliva topotecan concentration time course using a population approach. Oncol Res 13: 211-219.
2. Cawello W, Nickel B, Eggert-Formella A,. (2010) No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 50: 459-471.
3. Drobitch RK, Svensson CK,. (1992) Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet 23: 365-379.
4. EMA. (2001) The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98); London, July 26, 2001.
5. FDA. (1998) Draft guidance CDERGUID\1970DFT.WPD version Nov 1998, general considerations for pediatric pharmacokinetic studies for drugs and biological products. FDA, Rockville, MD.
6. FDA. (2001) Guidance for industry: bioanalytical method validation. US Department for Health and Human Services, Rockville, MD. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ default.html (accessed March 14, 2011).
7. FDA. (2002) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. Center for Drug Evaluation and Research; Draft July 2002, Rockville, MD.
8. Fountain NB, Conry JA, Rodriguez-Leyva I, Gutierrez-Moctezuma J, Salas E, Coupez R, Stockis A, Lu ZS,. (2007) Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res 74: 60-69.
9. Fountain N, Staelens L, Tytgat D, Rudd GD, Jacques P, Cawello W,. (2012) Low lacosamide plasma protein binding in lacosamide-naive patients (P01.077). Neurology 78: P01.077.
10. Fraser HS, Mucklow JC, Murray S, Davies DS,. (1976) Assessment of antipyrine kinetics by measurement in saliva. Br J Clin Pharmacol 3: 321-325.
11. Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD,. (2005) Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 45: 394-403.
12. Gandia P, Bareille MP, Saivin S, Le-Traon AP, Lavit M, Guell A, Houin G,. (2003) Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. J Clin Pharmacol 43: 1235-1243.
13. Gorodischer R, Koren G,. (1992) Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring. Dev Pharmacol Ther 19: 161-177.
14. Graham G, Rowland M,. (1972) Application of salivary salicylate data to biopharmaceutical studies of salicylates. J Pharm Sci 61: 1219-1222.
15. Greenaway C, Ratnaraj N, Sander JW, Patsalos PN,. (2011) Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 52: 258-263.
16. Incecayir T, Agabeyoglu I, Gucuyener K,. (2007) Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. Arzneimittelforschung 57: 517-521.
17. Lins RL, Otoul C, De Smedt F, Coupez R, Stockis A,. (2007) Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int J Clin Pharmacol Ther 45: 47-54.
18. Liu H, Delgado MR,. (1999) Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 36: 453-470.
19. Matin SB, Wan SH, Karam JH,. (1974) Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther 16: 1052-1058.
20. Nejem RM, Issa MM, Shaat NT,. (2007) Paracetamol bioavailability study by means of salivary samples. Pak J Biol Sci 10: 1553-1555.
21. Nickel B, Zisowsky J, Cawello W, Lovern M, Sargentini-Maier M, Labiner DM,. (2008) Population pharmacokinetics of lacosamide in subjects with partial-onset seizures: results from two phase III trials [abstract]. J Clin Pharmacol 48: 1099-1135.
22. Rauh M, Stachel D, Kuhlen M, Groschl M, Holter W, Rascher W,. (2006) Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children: validation of liquid chromatography tandem mass spectrometry method. Clin Pharmacokinet 45: 305-316.
23. Rodgers T, Rowland M,. (2006) Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95: 1238-1257.
24. Schaiquevich P, Niselman A, Rubio M,. (2002) Importance of entero-salivary recirculation in paracetamol pharmacokinetics. Biopharm Drug Dispos 23: 245-249.
25. Teneggi V, Squassante L, Iavarone L, Milleri S, Bye A, Gomeni R,. (2002) Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving. Br J Clin Pharmacol 54: 407-414.